Hot Biotech Companies To Watch For 2015

Hot Biotech Companies To Watch For 2015: Regeneron Pharmaceuticals Inc.(REGN)

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions in the United States. The company?s commercial product includes ARCALYST (rilonacept) injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its products under Phase III clinical development stage consist of VEGF Trap-Eye, an aflibercept ophthalmic solution developed using intraocular delivery for the treatment of serious eye diseases; ARCALYST for the prevention of gout flares in patients initiating uric acid-lowering treatment; and Aflibercept (VEGF Trap), which is developed in oncology. The company?s earlier stage clinical programs include various human antibodies, such as REGN727 for low-density lipoprotein cholesterol reduction, REGN88 for rheumatoid arthritis and ankylosing spondylitis; REGN668 for atopic dermatitis and asthma; REGN421 and REGN910 for oncology; REGN475 for the treatment of pain; and REGN728 and REGN846. It also conducts preclinical research programs in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. The company distributes its products through third party service providers. It has strategic collaboration with sanofi-aventis Group to discover, develop, and commercialize human monoclonal antibodies; and Bayer HealthCare LLC to develop and commercialize VEGF Trap. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is based in Tarrytown, New York.

Advisors' Opinion:

• [By Cynthia Andrade]

  Looking at the portfolio, 55% of assets are in large-caps, 25% in mid-caps and the re! mainder in small firms. The fund has 56% of assets in its top ten holdings, which include Biogen (BIIB), Gilead (GILD), Amgen (AMGN), Regeneron (REGN), and Celgene (CELG).

• [By Grace L. Williams]

  Youd hardly know biotech Regeneron Pharmaceuticals (REGN) reported a mixed first quarter this morning. Although the stock is down now, shares popped earlier, trading up as much as 1.8% around 10:30 a.m. before simmering down.

  For the period ended March 31, Regeneron reported earnings of $2.26 a share or $263 million, up from $1.78 or $201 million year-over-year. Revenue rose to $626 million compared to $440 million. Analysts polled by Thomson Reuters most recently forecast earnings of $2.20 a share, on sales of $610 million. The big downer: Disappointing sales of Regeneron’s eye treatment, Eylea.

  Citigroup analyst Yaron Werber, however, calls the weak sales a temporary setback and considers weakness in Regeneron a buying opportunity. He explains why:

  Eylea sales were a miss at $356 million versus our $409 million and Consensus $404 million, impacted by a decrease in distributor inventory and typically weak first quarter. Unit demand for Eylea grew by 25% year-over-year excluding inventory. The guidance was re-affirmed and we expect sales to bounce back in the second quarter and benefit from DME approval in the third quarter of 2014…This quarter was anticipated to be weak and any weakness in the stock provides an entry point ahead of a robust year of data for Alirocumab and dupilumab, ongoing strong ex-US launch of Eylea and expected approval in DME in the US by August 18th.

  Shares of Regeneron have dropped 1.7% to $281.81 at 3:116 p.m. The iShares Nasdaq Biotechnology ETF (IBB) has fallen 2% to $222.94, while the SPDR S&P Biotech ETF (XBI) has slid 3.8% to $120.

• [By Sean Williams]

  The lead drug
  This is actually the most difficult choice because there are so many top-performing lead drug candidates. In deciding ! which one! to choose I focused on a mixture of total sales potential, time until patent expiration, as well as the potential for indication expansion. I narrowed it down to two lead drug candidates: Celgene's (NASDAQ: CELG  ) Revlimid and Regeneron Pharmaceuticals' (NASDAQ: REGN  ) Eylea.

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/hot-biotech-companies-to-watch-for-2015-2.html